Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...
The FDA has specified use of the Ventana Pathway anti-HER2/neu (4B5) antibody assay. Additionally, the American Society for Clinical Pathology has guidelines for testing for HER2. Support for the ...
Hosted on MSN1mon
The Most Effective HER2-Positive Breast Cancer TreatmentsThe mutation causes the gene to produce too many HER2/neu proteins (or just HER2 proteins). In normal amounts, these proteins act as receptors that tell the breast cells how much to grow (and when ...
Hosted on MSN1mon
FDA approves Roche’s PATHWAY HER2 test for biliary tract cancerThe US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC).
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
In some men with breast cancer, the cancer cells have too much of a growth-promoting protein known as HER2 (or HER2/neu) on their surface. These cancers, known as HER2-positive breast cancers, tend to ...
Breast Receptor status: Any tumor ER/PgR status, any HER2/neu status as measured by local hospital pathology laboratory, and meets any tumor assay profile described in protocol. Tumors will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback